Eledon Pharmaceuticals Publishes Presentation on Patient-Reported Outcomes in Phase 2 BESTOW Trial

• Eledon Pharmaceuticals published its ASN Kidney Week 2026 presentation on patient-reported outcomes from the Phase 2 BESTOW kidney transplant trial.
• Tegoprubart improved all five quality-of-life subscales through Month 12, compared with four of five for tacrolimus.
• Symptoms and problems scores improved 9.0 points with tegoprubart versus 3.3 with tacrolimus, a statistically significant difference (p < 0.05).
• Month 12 symptom occurrence scores were significantly lower with tegoprubart at 18.6 versus 25.7 with tacrolimus.
• Kidney function was higher with tegoprubart across all measurable time points; biopsy-proven acute rejection did not differ between groups at Month 12.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eledon Pharmaceuticals Inc. published the original content used to generate this news brief on October 26, 2026, and is solely responsible for the information contained therein.